{"id":8559,"date":"2026-04-30T05:02:41","date_gmt":"2026-04-30T05:02:41","guid":{"rendered":"https:\/\/quantstrategy.io\/blog\/future-of-glp-1-exploring-next-gen-oral-weight-loss\/"},"modified":"2026-04-30T05:02:41","modified_gmt":"2026-04-30T05:02:41","slug":"future-of-glp-1-exploring-next-gen-oral-weight-loss","status":"publish","type":"post","link":"https:\/\/quantstrategy.io\/blog\/future-of-glp-1-exploring-next-gen-oral-weight-loss\/","title":{"rendered":"Future of GLP-1: Exploring Next-Gen Oral Weight Loss Medications"},"content":{"rendered":"<p><img decoding=\"async\" src=\"https:\/\/quantstrategy.io\/blog\/wp-content\/uploads\/2026\/05\/science_research_white_pexels_5.jpg\" alt=Future of GLP-1: Exploring><br \/>\nThe landscape of metabolic health is undergoing a seismic shift, moving from the era of weekly injections to the highly anticipated arrival of daily pills. As part of <a href=\"https:\/\/quantstrategy.io\/blog\/the-ultimate-glp-1-investing-strategy-for-2026-navigating\">The Ultimate GLP-1 Investing Strategy for 2026: Navigating the Weight Loss Drug Market<\/a>, understanding the <strong>Future of GLP-1: Exploring Next-Gen Oral Weight Loss Medications<\/strong> is critical for investors and healthcare providers alike. While injectables like Wegovy and Zepbound have proven their efficacy, the market\u2019s next &#8220;gold rush&#8221; lies in small-molecule orals that promise greater convenience, lower manufacturing costs, and broader patient accessibility. This evolution represents more than just a change in delivery method; it signifies a massive expansion of the total addressable market (TAM) as the barrier to entry for patients\u2014fear of needles and complex storage requirements\u2014is effectively removed.<\/p>\n<h2 id=\"the-strategic-shift-from-injectables-to-oral-formulations\">The Strategic Shift from Injectables to Oral Formulations<\/h2>\n<p>The current generation of GLP-1 agonists is dominated by peptides. Peptides are large molecules that are easily broken down by stomach acid, which is why they are typically administered via subcutaneous injection. However, the future hinges on &#8220;small molecule&#8221; drugs. These are chemically synthesized compounds designed to withstand the digestive environment and cross the gut barrier into the bloodstream.<\/p>\n<p>From an investment perspective, the shift to orals addresses three primary bottlenecks currently facing the industry:<\/p>\n<ul>\n<li><strong>Manufacturing Scalability:<\/strong> Injectables require sterile fill-finish facilities and cold-chain logistics, which are expensive and slow to build. Oral pills can be manufactured using traditional chemical synthesis in existing facilities, significantly increasing supply.<\/li>\n<li><strong>Patient Adherence:<\/strong> Many patients remain &#8220;needle-phobic.&#8221; A daily pill integrates more naturally into a patient&#8217;s routine than a weekly injection, potentially increasing long-term compliance and recurring revenue for pharmaceutical companies.<\/li>\n<li><strong>Payer Accessibility:<\/strong> If oral versions can be produced at a lower cost, they may facilitate easier negotiations with insurance companies and pharmacy benefit managers (PBMs), broadening coverage.<\/li>\n<\/ul>\n<p>As you refine your portfolio, understanding these dynamics is essential. For a broader look at the current market leaders, see our analysis of <a href=\"https:\/\/quantstrategy.io\/blog\/eli-lilly-vs-novo-nordisk-a-deep-dive-stock-analysis-for\">Eli Lilly vs. Novo Nordisk: A Deep Dive Stock Analysis for Long-Term Investors<\/a>.<\/p>\n<h2 id=\"the-science-of-bioavailability-and-small-molecules\">The Science of Bioavailability and Small Molecules<\/h2>\n<p>The primary hurdle in developing the <strong>Future of GLP-1: Exploring Next-Gen Oral Weight Loss Medications<\/strong> has been bioavailability\u2014ensuring enough of the drug survives the stomach to be effective. Early oral attempts, such as Rybelsus, required large doses of peptides and strict fasting protocols to work. Next-gen orals are moving toward &#8220;non-peptide small molecule agonists.&#8221;<\/p>\n<p>These molecules are designed using advanced computational methods. Companies are increasingly leveraging <a href=\"https:\/\/quantstrategy.io\/blog\/the-impact-of-ai-and-ml-models-on-drug-discovery-for\">The Impact of AI and ML Models on Drug Discovery for Obesity Treatments<\/a> to simulate how these small molecules interact with the GLP-1 receptor. By predicting binding affinity and metabolic stability, researchers can skip years of trial-and-error in the lab.<\/p>\n<h2 id=\"case-study-1-eli-lillys-orforglipron\">Case Study 1: Eli Lilly\u2019s Orforglipron<\/h2>\n<p>Eli Lilly is currently leading the charge with Orforglipron, a non-peptide GLP-1 receptor agonist. Unlike oral semaglutide, Orforglipron does not have the same stringent fasting requirements, making it much more patient-friendly.<\/p>\n<p><strong>Key Insights:<\/strong><\/p>\n<ul>\n<li><strong>Clinical Data:<\/strong> Phase 2 trials showed weight loss comparable to injectable semaglutide, with participants losing up to 14.7% of their body weight over 36 weeks.<\/li>\n<li><strong>Market Impact:<\/strong> Because it is a small molecule, Lilly can produce it at a scale that injectables cannot match. This could potentially allow Lilly to capture the mid-tier market where patients may not need the extreme weight loss of Zepbound but want the metabolic benefits of GLP-1s.<\/li>\n<\/ul>\n<p>Investors monitoring these developments should also consider <a href=\"https:\/\/quantstrategy.io\/blog\/etf-strategies-for-glp-1-exposure-diversifying-your\">ETF Strategies for GLP-1 Exposure: Diversifying Your Healthcare Portfolio<\/a> to mitigate the clinical trial risk of individual stocks.<\/p>\n<h2 id=\"case-study-2-structure-therapeutics-gsbr-and-the-small-cap-opportunity\">Case Study 2: Structure Therapeutics (GSBR) and the Small-Cap Opportunity<\/h2>\n<p>While the &#8220;Big Two&#8221; dominate headlines, smaller biotech firms are making significant strides in oral GLP-1 technology. Structure Therapeutics is a prime example of a company focused exclusively on G-protein-coupled receptor (GPCR) targeting.<\/p>\n<p><strong>Clinical Progress:<\/strong> Their lead candidate, GSBR-1290, is an oral small molecule GLP-1 agonist. Recent Phase 2a data showed promising weight loss and a favorable safety profile. For investors, companies like Structure represent a &#8220;pure-play&#8221; on the oral GLP-1 thesis. These stocks are often more volatile but offer higher upside if they become acquisition targets for larger pharma companies looking to bolster their pipelines. To identify similar opportunities, explore our list of the <a href=\"https:\/\/quantstrategy.io\/blog\/top-5-best-weight-loss-drug-stocks-to-watch-beyond-the-big\">Top 5 Best Weight Loss Drug Stocks to Watch Beyond the Big Two<\/a>.<\/p>\n<h2 id=\"comparing-oral-vs-injectable-glp-1-agonists\">Comparing Oral vs. Injectable GLP-1 Agonists<\/h2>\n<table style=\"width:100%; border: 1px solid #ddd; border-collapse: collapse;\">\n<thead>\n<tr style=\"background-color: #f2f2f2;\">\n<th style=\"padding: 10px; border: 1px solid #ddd;\">Feature<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd;\">Injectables (Current)<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd;\">Next-Gen Orals (Future)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Administration<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Weekly Subcutaneous<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Daily Pill<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Manufacturing<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Biologics (Complex\/Slow)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Chemical Synthesis (Scalable)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Logistics<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Cold-Chain Required<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Room Temperature Stable<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Bioavailability<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">100% (Direct Entry)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Variable (1% &#8211; 10%)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2 id=\"investment-implications-for-2026\">Investment Implications for 2026<\/h2>\n<p>As we look toward 2026, the <strong>Future of GLP-1: Exploring Next-Gen Oral Weight Loss Medications<\/strong> will likely dictate which companies maintain their market cap premiums. We are seeing a shift where <a href=\"https:\/\/quantstrategy.io\/blog\/psychology-of-the-market-why-weight-loss-stocks-are-the-new\">Weight Loss Stocks Are the New Tech Giants<\/a>, driven by recurring revenue models and massive consumer demand.<\/p>\n<p>To capitalize on this, sophisticated investors are using data-driven approaches. You can learn <a href=\"https:\/\/quantstrategy.io\/blog\/how-to-backtest-a-biotech-portfolio-glp-1-sector\">How to Backtest a Biotech Portfolio: GLP-1 Sector Performance Analysis<\/a> to see how previous oral drug launches impacted stock prices. Additionally, timing is everything in biotech; utilizing <a href=\"https:\/\/quantstrategy.io\/blog\/technical-indicators-for-timing-entries-in-eli-lilly-and\">Technical Indicators for Timing Entries in Eli Lilly and Novo Nordisk<\/a> can help you navigate the volatility that often accompanies Phase 3 trial results.<\/p>\n<p>For those concerned about the inherent risks of clinical failures, utilizing <a href=\"https:\/\/quantstrategy.io\/blog\/options-trading-strategies-for-volatile-biotech-earnings\">Options Trading Strategies for Volatile Biotech Earnings: GLP-1 Edition<\/a> provides a way to hedge against downside while maintaining exposure to the &#8220;oral revolution.&#8221;<\/p>\n<h2 id=\"conclusion-the-road-to-2026\">Conclusion: The Road to 2026<\/h2>\n<p>The <strong>Future of GLP-1: Exploring Next-Gen Oral Weight Loss Medications<\/strong> is set to redefine the obesity treatment market. By solving the challenges of manufacturing and patient convenience, oral small molecules will likely become the standard of care for millions. For investors, the focus must shift from simply &#8220;who has the best injectable&#8221; to &#8220;who can successfully bring a stable, effective oral pill to market.&#8221; This transition will create immense value but also significant volatility as clinical trials reach their endpoints.<\/p>\n<p>For a comprehensive view of how to position your portfolio for the coming years, return to our primary guide: <a href=\"https:\/\/quantstrategy.io\/blog\/the-ultimate-glp-1-investing-strategy-for-2026-navigating\">The Ultimate GLP-1 Investing Strategy for 2026: Navigating the Weight Loss Drug Market<\/a>. Understanding the role of <a href=\"https:\/\/quantstrategy.io\/blog\/the-role-of-alpha-lab-research-in-identifying-undervalued\">Alpha Lab Research in Identifying Undervalued Biotech Stocks<\/a> can further enhance your ability to spot winners before the broader market catches on.<\/p>\n<h2 id=\"frequently-asked-questions\">Frequently Asked Questions<\/h2>\n<p><strong>1. Why are oral GLP-1s considered the &#8220;next-gen&#8221; of weight loss?<\/strong><br \/>\nOral medications are more convenient than injections, do not require refrigeration, and can be produced at a significantly larger scale using chemical synthesis. This makes them more accessible to a global population.<\/p>\n<p><strong>2. Are oral GLP-1 medications as effective as injections?<\/strong><br \/>\nEarly data from drugs like Eli Lilly\u2019s Orforglipron suggests that next-gen orals can achieve weight loss results nearly comparable to current injectables, though injectables may still hold a slight edge in total percentage of weight lost for the most severe cases.<\/p>\n<p><strong>3. When will these oral weight loss pills be available?<\/strong><br \/>\nSeveral oral candidates are currently in Phase 3 trials. Based on standard FDA timelines, we expect the first wave of next-gen non-peptide orals to receive approval and hit the market between 2025 and 2027.<\/p>\n<p><strong>4. How do oral GLP-1s impact the supply chain issues currently facing Wegovy and Zepbound?<\/strong><br \/>\nBecause orals are small molecules produced via chemical synthesis, they don&#8217;t require the specialized biologic &#8220;fill-finish&#8221; capacity that currently limits the production of injectable GLP-1s, potentially ending the chronic shortages.<\/p>\n<p><strong>5. Which companies are the leaders in the oral GLP-1 space?<\/strong><br \/>\nEli Lilly (Orforglipron) and Novo Nordisk (oral semaglutide and Amycretin) are the frontrunners, but smaller firms like Structure Therapeutics and Viking Therapeutics are developing competitive candidates.<\/p>\n<p><strong>6. What is the main risk for investors in oral GLP-1 medications?<\/strong><br \/>\nThe primary risks are clinical trial failures (efficacy or safety concerns) and the potential for lower &#8220;bioavailability,&#8221; which means the drug might not work consistently across all patients due to individual digestive differences.<\/p>\n<p><strong>7. How does the development of orals fit into a long-term GLP-1 investing strategy?<\/strong><br \/>\nOrals are a key component of the 2026 strategy because they represent the &#8220;mass market&#8221; phase of the industry, moving from high-cost specialty medicine to a more broadly prescribed daily metabolic health pill.<\/p>\n","protected":false},"excerpt":{"rendered":"The landscape of metabolic health is undergoing a seismic shift, moving from the era of weekly injections to&hellip;\n","protected":false},"author":1,"featured_media":8558,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[66,67],"tags":[],"class_list":{"0":"post-8559","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-stocks-and-etfs","8":"category-theme-investing"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.9.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Future of GLP-1: Exploring Next-Gen Oral Weight Loss Medications - Learn Quant Trading | QuantStrategy.io<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/quantstrategy.io\/blog\/future-of-glp-1-exploring-next-gen-oral-weight-loss\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Future of GLP-1: Exploring Next-Gen Oral Weight Loss Medications - Learn Quant Trading | QuantStrategy.io\" \/>\n<meta property=\"og:description\" content=\"The landscape of metabolic health is undergoing a seismic shift, moving from the era of weekly injections to&hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/quantstrategy.io\/blog\/future-of-glp-1-exploring-next-gen-oral-weight-loss\/\" \/>\n<meta property=\"og:site_name\" content=\"Learn Quant Trading | QuantStrategy.io\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-30T05:02:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/quantstrategy.io\/blog\/wp-content\/uploads\/2026\/05\/science_research_white_pexels_5.jpg\" \/>\n<meta name=\"author\" content=\"QuantStrategy.io Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"QuantStrategy.io Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Future of GLP-1: Exploring Next-Gen Oral Weight Loss Medications - Learn Quant Trading | QuantStrategy.io","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/quantstrategy.io\/blog\/future-of-glp-1-exploring-next-gen-oral-weight-loss\/","og_locale":"en_US","og_type":"article","og_title":"Future of GLP-1: Exploring Next-Gen Oral Weight Loss Medications - Learn Quant Trading | QuantStrategy.io","og_description":"The landscape of metabolic health is undergoing a seismic shift, moving from the era of weekly injections to&hellip;","og_url":"https:\/\/quantstrategy.io\/blog\/future-of-glp-1-exploring-next-gen-oral-weight-loss\/","og_site_name":"Learn Quant Trading | QuantStrategy.io","article_published_time":"2026-04-30T05:02:41+00:00","og_image":[{"url":"https:\/\/quantstrategy.io\/blog\/wp-content\/uploads\/2026\/05\/science_research_white_pexels_5.jpg"}],"author":"QuantStrategy.io Team","twitter_card":"summary_large_image","twitter_misc":{"Written by":"QuantStrategy.io Team","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/quantstrategy.io\/blog\/future-of-glp-1-exploring-next-gen-oral-weight-loss\/#article","isPartOf":{"@id":"https:\/\/quantstrategy.io\/blog\/future-of-glp-1-exploring-next-gen-oral-weight-loss\/"},"author":{"name":"QuantStrategy.io Team","@id":"https:\/\/quantstrategy.io\/blog\/#\/schema\/person\/63aef420d635f0dc50f9ba974f6c95d1"},"headline":"Future of GLP-1: Exploring Next-Gen Oral Weight Loss Medications","datePublished":"2026-04-30T05:02:41+00:00","dateModified":"2026-04-30T05:02:41+00:00","mainEntityOfPage":{"@id":"https:\/\/quantstrategy.io\/blog\/future-of-glp-1-exploring-next-gen-oral-weight-loss\/"},"wordCount":1350,"publisher":{"@id":"https:\/\/quantstrategy.io\/blog\/#organization"},"articleSection":["Stocks and ETFs","Theme Investing"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/quantstrategy.io\/blog\/future-of-glp-1-exploring-next-gen-oral-weight-loss\/","url":"https:\/\/quantstrategy.io\/blog\/future-of-glp-1-exploring-next-gen-oral-weight-loss\/","name":"Future of GLP-1: Exploring Next-Gen Oral Weight Loss Medications - Learn Quant Trading | QuantStrategy.io","isPartOf":{"@id":"https:\/\/quantstrategy.io\/blog\/#website"},"datePublished":"2026-04-30T05:02:41+00:00","dateModified":"2026-04-30T05:02:41+00:00","breadcrumb":{"@id":"https:\/\/quantstrategy.io\/blog\/future-of-glp-1-exploring-next-gen-oral-weight-loss\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/quantstrategy.io\/blog\/future-of-glp-1-exploring-next-gen-oral-weight-loss\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/quantstrategy.io\/blog\/future-of-glp-1-exploring-next-gen-oral-weight-loss\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/quantstrategy.io\/blog\/"},{"@type":"ListItem","position":2,"name":"Future of GLP-1: Exploring Next-Gen Oral Weight Loss Medications"}]},{"@type":"WebSite","@id":"https:\/\/quantstrategy.io\/blog\/#website","url":"https:\/\/quantstrategy.io\/blog\/","name":"QuantStrategy.io - blog","description":"Blog","publisher":{"@id":"https:\/\/quantstrategy.io\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/quantstrategy.io\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/quantstrategy.io\/blog\/#organization","name":"QuantStrategy.io","url":"https:\/\/quantstrategy.io\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/quantstrategy.io\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/quantstrategy.io\/blog\/wp-content\/uploads\/2023\/11\/qs_io_logo-80.png","contentUrl":"https:\/\/quantstrategy.io\/blog\/wp-content\/uploads\/2023\/11\/qs_io_logo-80.png","width":80,"height":80,"caption":"QuantStrategy.io"},"image":{"@id":"https:\/\/quantstrategy.io\/blog\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/quantstrategy.io\/blog\/#\/schema\/person\/63aef420d635f0dc50f9ba974f6c95d1","name":"QuantStrategy.io Team","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/quantstrategy.io\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/23922b0b6b220e6e9aca4c738eace72e744af8c32a4b3ee7ca8d7bbb8fc8d5b2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/23922b0b6b220e6e9aca4c738eace72e744af8c32a4b3ee7ca8d7bbb8fc8d5b2?s=96&d=mm&r=g","caption":"QuantStrategy.io Team"},"sameAs":["https:\/\/quantstrategy.io\/blog"],"url":"https:\/\/quantstrategy.io\/blog\/author\/razmik_davtyan\/"}]}},"_links":{"self":[{"href":"https:\/\/quantstrategy.io\/blog\/wp-json\/wp\/v2\/posts\/8559","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/quantstrategy.io\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/quantstrategy.io\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/quantstrategy.io\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/quantstrategy.io\/blog\/wp-json\/wp\/v2\/comments?post=8559"}],"version-history":[{"count":0,"href":"https:\/\/quantstrategy.io\/blog\/wp-json\/wp\/v2\/posts\/8559\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/quantstrategy.io\/blog\/wp-json\/wp\/v2\/media\/8558"}],"wp:attachment":[{"href":"https:\/\/quantstrategy.io\/blog\/wp-json\/wp\/v2\/media?parent=8559"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/quantstrategy.io\/blog\/wp-json\/wp\/v2\/categories?post=8559"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/quantstrategy.io\/blog\/wp-json\/wp\/v2\/tags?post=8559"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}